Published in Clin Cancer Res on July 01, 2007
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res (2011) 1.47
The colony-stimulating factors and cancer. Nat Rev Cancer (2010) 1.44
Cellular vaccine approaches. Cancer J (2010) 1.27
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs (2008) 1.08
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med (2010) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer (2014) 0.86
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate (2011) 0.86
Role of GM-CSF signaling in cell-based tumor immunization. Blood (2009) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol (2009) 0.85
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer (2015) 0.84
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother (2015) 0.83
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int (2015) 0.82
In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. PLoS One (2013) 0.82
Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins (Basel) (2012) 0.82
Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82
Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor. Cancer Immunol Immunother (2009) 0.82
From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J (2016) 0.79
Emerging vaccine therapy approaches for prostate cancer. Rev Urol (2010) 0.78
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther (2011) 0.78
Immunotherapy for prostate cancer: False promises or true hope? Cancer (2016) 0.78
Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs (2008) 0.77
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol (2014) 0.77
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol (2011) 0.77
Glycan array analysis of the antigen repertoire targeted by tumor-binding antibodies. Bioorg Med Chem Lett (2012) 0.77
Intensifying tumour immunity through combination therapy. Lancet Oncol (2012) 0.76
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. Onco Targets Ther (2017) 0.75
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy. Avicenna J Med (2011) 0.75
Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem (2009) 0.75
Antitumor cell-complex vaccines employing genetically modified tumor cells and fibroblasts. Toxins (Basel) (2014) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
Immunotherapy in metastatic prostate cancer. Indian J Urol (2016) 0.75
Immunotherapy in genitourinary malignancies. J Hematol Oncol (2017) 0.75
Advances on immunotherapy in genitourinary and renal cell carcinoma. Transl Cancer Res (2017) 0.75
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. Front Immunol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig. Nature (2003) 5.41
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
Nanotechnology applications in cancer. Annu Rev Biomed Eng (2007) 3.88
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc (2007) 2.45
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab (2007) 2.36
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol (2007) 2.26
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05
Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest (2005) 1.96
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem (2005) 1.84
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res (2003) 1.82
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther (2005) 1.81
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem (2002) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol (2005) 1.69
Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res (2005) 1.66
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene (2005) 1.64
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59
A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics (2002) 1.58
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem (2004) 1.56
Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem (2005) 1.56
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates. J Immunol (2008) 1.52
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest (2004) 1.51
Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther (2008) 1.51
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol (2003) 1.50
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther (2005) 1.46
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res (2005) 1.46
Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol (2009) 1.45
Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife (2013) 1.44
KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer (2006) 1.44
Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. J Am Coll Cardiol (2007) 1.43
Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther (2005) 1.40